![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay & Daniel Krewski. (2018) Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology 48:1, pages 52-108.
Read now
Read now
Bhavik J. Pandya, Morgan Bron, Therese McCall, Andrew P. Yu, Kristina S. Chen, Miles E. Mattson & Eric Q. Wu. (2011) Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. Current Medical Research and Opinion 27:1, pages 189-195.
Read now
Read now
Pedro de Pablos-Velasco. (2010) Pioglitazone: beyond glucose control. Expert Review of Cardiovascular Therapy 8:8, pages 1057-1067.
Read now
Read now
Articles from other publishers (16)
Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie & Linong Ji. (2020) Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Medicine 18:1.
Crossref
Crossref
Xiao-Ling Cai & Li-Nong Ji. (2019) Treatment response between Asian and non-Asian patients with type 2 diabetes. Chinese Medical Journal 132:1, pages 1-3.
Crossref
Crossref
L. M. Neff, M. S. Broder, D. Beenhouwer, E. Chang, E. Papoyan & Z. W. Wang. (2017) Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity. Clinical Obesity 7:6, pages 337-346.
Crossref
Crossref
Dennis Schrijnders, Raiza Wever, Nanne Kleefstra, Sebastiaan T. Houweling, Kornelis J. J. van Hateren, Geertruida H. de Bock, Henk J. G. Bilo, Klaas H. Groenier & Gijs W. D. Landman. (2016)
Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (
ZODIAC
‐39)
. Diabetes, Obesity and Metabolism 18:10, pages 973-979.
Crossref
Crossref
Oded Stempa. (2015) Pioglitazone: lessons and learnings 15 years since launch and beyond. Diabetes Management 5:6, pages 415-429.
Crossref
Crossref
James H. Flory & Alvin I. Mushlin. (2015) Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement. Journal of Clinical Epidemiology 68:2, pages 200-210.
Crossref
Crossref
M. Bajaj, R. Gilman, S. Patel, J. Kempthorne‐Rawson, D. Lewis‐D'Agostino & H.‐J. Woerle. (2014) Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24‐week randomized, double‐blind study. Diabetic Medicine 31:12, pages 1505-1514.
Crossref
Crossref
Young Ki LeeSun Ok SongKwang Joon KimYongin ChoYounjeong ChoiYujung YunByung-Wan LeeEun-Seok KangBong Soo ChaHyun Chul Lee. (2013) Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients. Diabetes & Metabolism Journal 37:6, pages 465.
Crossref
Crossref
Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Takaki Hayakawa, Norihito Yoshioka & Koji Kawakami. (2012) Evaluation of the bioequivalence of a fixed-dose combination tablet of pioglitazone–metformin versus commercial tablets in healthy Japanese male volunteers. Diabetes Management 2:5s, pages 13-20.
Crossref
Crossref
S.‐C. Liu, Y.‐K. Tu, M.‐N. Chien & K.‐L. Chien. (2012) Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis. Diabetes, Obesity and Metabolism 14:9, pages 810-820.
Crossref
Crossref
Debora MacisSara GandiniAliana Guerrieri-GonzagaHarriet JohanssonPaolo MagniMassimiliano RuscicaMatteo LazzeroniDavide SerranoMassimiliano CazzanigaSerena MoraIrene FeroceMaria PizzamiglioMaria Teresa SandriMarcella GulisanoBernardo BonanniAndrea DeCensi. (2012) Prognostic Effect of Circulating Adiponectin in a Randomized 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer. Journal of Clinical Oncology 30:2, pages 151-157.
Crossref
Crossref
A. Avogaro, M. Federici, J. Betteridge, R. Bonadonna, I. W. Campbell, G. H. Schernthaner, B. Staels, E. Farinaro & G. Crepaldi. (2014) Which is the eligible patient to be treated with pioglitazone? The expert view. Journal of Endocrinological Investigation 34:10, pages 781-787.
Crossref
Crossref
Esther Phielix, Julia Szendroedi & Michael Roden. (2011) The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends in Pharmacological Sciences 32:10, pages 607-616.
Crossref
Crossref
Lucio Vilar, Viviane Canadas, Maria Juliana Arruda, Carla Arahata, Rodrigo Agra, Lisete Pontes, Larissa Montenegro, Clarice Freitas Vilar, Lidiane Moura e Silva, José Luciano Albuquerque & Amaro Gusmão. (2010) Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arquivos Brasileiros de Endocrinologia & Metabologia 54:3, pages 311-318.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter (posthumous). 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:12.
Crossref
Crossref